Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis.

Jacobson W, Zhong W, Nomikos GG, Christensen MC, Kurre Olsen C, Harvey PD.

Curr Med Res Opin. 2020 Jan;36(1):117-124. doi: 10.1080/03007995.2019.1657692. Epub 2019 Aug 29.

PMID:
31422713
2.

SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies.

Hoffmann E, Nomikos GG, Kaul I, Raines S, Wald J, Bullock A, Sankoh AJ, Doherty J, Kanes SJ, Colquhoun H.

Clin Pharmacokinet. 2019 Jul 24. doi: 10.1007/s40262-019-00801-0. [Epub ahead of print]

PMID:
31338688
3.

Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram.

Jacobsen PL, Nomikos GG, Zhong W, Cutler AJ, Affinito J, Clayton A.

CNS Spectr. 2019 Apr 23:1-14. doi: 10.1017/S1092852919000750. [Epub ahead of print]

PMID:
31010445
4.

Effects of Intrinsic Factors on the Clinical Pharmacokinetics of Vortioxetine.

Chen G, Nomikos GG, Affinito J, Jacobson W, Zhao Z, Wang S, Xie J.

Clin Pharmacol Drug Dev. 2018 Nov;7(8):880-888. doi: 10.1002/cpdd.577. Epub 2018 Jun 19.

PMID:
29920978
5.

Adolescent Female Cannabinoid Exposure Diminishes the Reward-Facilitating Effects of Δ9-Tetrahydrocannabinol and d-Amphetamine in the Adult Male Offspring.

Pitsilis G, Spyridakos D, Nomikos GG, Panagis G.

Front Pharmacol. 2017 Apr 25;8:225. doi: 10.3389/fphar.2017.00225. eCollection 2017.

6.

Determination of a clinically important difference and definition of a responder threshold for the UCSD performance-based skills assessment (UPSA) in patients with major depressive disorder.

Harvey PD, Jacobson W, Zhong W, Nomikos GG, Cronquist Christensen M, Kurre Olsen C, Merikle E.

J Affect Disord. 2017 Apr 15;213:105-111. doi: 10.1016/j.jad.2017.02.014. Epub 2017 Feb 14.

7.

Attenuation of Cocaine-Induced Conditioned Place Preference and Motor Activity via Cannabinoid CB2 Receptor Agonism and CB1 Receptor Antagonism in Rats.

Delis F, Polissidis A, Poulia N, Justinova Z, Nomikos GG, Goldberg SR, Antoniou K.

Int J Neuropsychopharmacol. 2017 Mar 1;20(3):269-278. doi: 10.1093/ijnp/pyw102.

8.

Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.

Nomikos GG, Tomori D, Zhong W, Affinito J, Palo W.

CNS Spectr. 2017 Aug;22(4):348-362. doi: 10.1017/S1092852916000626. Epub 2016 Nov 21.

PMID:
27869048
9.

A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.

Baldwin DS, Florea I, Jacobsen PL, Zhong W, Nomikos GG.

J Affect Disord. 2016 Dec;206:140-150. doi: 10.1016/j.jad.2016.07.015. Epub 2016 Jul 7.

10.

Lack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium.

Chen G, Nomikos GG, Affinito J, Zhao Z.

Clin Pharmacokinet. 2016 Sep;55(9):1115-27. doi: 10.1007/s40262-016-0389-0.

11.

The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.

Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, Reines E.

J Psychopharmacol. 2016 Mar;30(3):242-52. doi: 10.1177/0269881116628440. Epub 2016 Feb 9.

12.

Behavioral and neurochemical changes in mesostriatal dopaminergic regions of the rat after chronic administration of the cannabinoid receptor agonist WIN55,212-2.

Fanarioti E, Mavrikaki M, Panagis G, Mitsacos A, Nomikos GG, Giompres P.

Int J Neuropsychopharmacol. 2014 Dec 7;18(6). pii: pyu097. doi: 10.1093/ijnp/pyu097.

13.

WIN55,212-2 impairs non-associative recognition and spatial memory in rats via CB1 receptor stimulation.

Galanopoulos A, Polissidis A, Georgiadou G, Papadopoulou-Daifoti Z, Nomikos GG, Pitsikas N, Antoniou K.

Pharmacol Biochem Behav. 2014 Sep;124:58-66. doi: 10.1016/j.pbb.2014.05.014. Epub 2014 May 24.

PMID:
24867078
14.

Ropinirole regulates emotionality and neuronal activity markers in the limbic forebrain.

Mavrikaki M, Schintu N, Nomikos GG, Panagis G, Svenningsson P.

Int J Neuropsychopharmacol. 2014 Dec;17(12):1981-93. doi: 10.1017/S1461145714000728. Epub 2014 May 23.

PMID:
24852388
15.

Effects of lithium and aripiprazole on brain stimulation reward and neuroplasticity markers in the limbic forebrain.

Mavrikaki M, Schintu N, Kastellakis A, Nomikos GG, Svenningsson P, Panagis G.

Eur Neuropsychopharmacol. 2014 Apr;24(4):630-8. doi: 10.1016/j.euroneuro.2013.10.014. Epub 2013 Nov 8.

PMID:
24275700
16.

Effect of Vortioxetine on Cardiac Repolarization in Healthy Adult Male Subjects: Results of a Thorough QT/QTc Study.

Wang Y, Nomikos GG, Karim A, Munsaka M, Serenko M, Liosatos M, Harris S.

Clin Pharmacol Drug Dev. 2013 Oct;2(4):298-309. doi: 10.1002/cpdd.51. Epub 2013 Aug 16.

PMID:
27121934
17.

In vivo occupancy of dopamine D3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder.

Barth V, Need AB, Tzavara ET, Giros B, Overshiner C, Gleason SD, Wade M, Johansson AM, Perry K, Nomikos GG, Witkin JM.

J Pharmacol Exp Ther. 2013 Feb;344(2):501-10. doi: 10.1124/jpet.112.198895. Epub 2012 Nov 29.

PMID:
23197772
18.

Modulation of neurotransmitter release in orexin/hypocretin-2 receptor knockout mice: a microdialysis study.

Ortega JE, Katner J, Davis R, Wade M, Nisenbaum L, Nomikos GG, Svensson KA, Perry KW.

J Neurosci Res. 2012 Mar;90(3):588-96. doi: 10.1002/jnr.22781. Epub 2011 Oct 31.

PMID:
22038504
19.

Δ(9)-THC and WIN55,212-2 affect brain tissue levels of excitatory amino acids in a phenotype-, compound-, dose-, and region-specific manner.

Galanopoulos A, Polissidis A, Papadopoulou-Daifoti Z, Nomikos GG, Antoniou K.

Behav Brain Res. 2011 Oct 10;224(1):65-72. doi: 10.1016/j.bbr.2011.05.018. Epub 2011 May 27.

PMID:
21645556
20.

Effects of olanzapine on extracellular concentrations and tissue content of neurotensin in rat brain regions.

Gruber SH, Angelucci F, Nomikos GG, Mathé AA.

Eur Neuropsychopharmacol. 2011 Dec;21(12):918-27. doi: 10.1016/j.euroneuro.2011.01.003. Epub 2011 Feb 12.

PMID:
21316929
21.

Chronic WIN55,212-2 elicits sustained and conditioned increases in intracranial self-stimulation thresholds in the rat.

Mavrikaki M, Markaki E, Nomikos GG, Panagis G.

Behav Brain Res. 2010 May 1;209(1):114-8. doi: 10.1016/j.bbr.2010.01.024. Epub 2010 Jan 25.

PMID:
20097234
22.

Efficacy of the atypical antipsychotic aripiprazole in d-amphetamine-based preclinical models of mania.

Mavrikaki M, Nomikos GG, Panagis G.

Int J Neuropsychopharmacol. 2010 May;13(4):541-8. doi: 10.1017/S1461145709991143. Epub 2010 Jan 5.

PMID:
20047715
23.

Individual differences in the effects of cannabinoids on motor activity, dopaminergic activity and DARPP-32 phosphorylation in distinct regions of the brain.

Polissidis A, Chouliara O, Galanopoulos A, Rentesi G, Dosi M, Hyphantis T, Marselos M, Papadopoulou-Daifoti Z, Nomikos GG, Spyraki C, Tzavara ET, Antoniou K.

Int J Neuropsychopharmacol. 2010 Oct;13(9):1175-91. doi: 10.1017/S1461145709991003. Epub 2009 Nov 27.

PMID:
19941698
24.
25.

CB1 receptor knockout mice are hyporesponsive to the behavior-stimulating actions of d-amphetamine: role of mGlu5 receptors.

Tzavara ET, Degroot A, Wade MR, Davis RJ, Nomikos GG.

Eur Neuropsychopharmacol. 2009 Mar;19(3):196-204. doi: 10.1016/j.euroneuro.2008.11.003. Epub 2008 Dec 29.

PMID:
19116182
26.

Effects of mood stabilizers on brain reward processes in rats: studies using the intracranial self-stimulation paradigm.

Mavrikaki M, Nomikos GG, Panagis G.

Eur Neuropsychopharmacol. 2009 Mar;19(3):205-14. doi: 10.1016/j.euroneuro.2008.11.002. Epub 2008 Dec 24.

PMID:
19110403
27.

Role of metabotropic glutamate receptor 5 in the procholinergic effects of neuropsychotherapeutic compounds.

Tzavara ET, Wade MR, Davis RJ, El Khoury MA, Nomikos GG.

Synapse. 2008 Dec;62(12):940-3. doi: 10.1002/syn.20560.

PMID:
18798268
28.

Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas.

Perry KW, Falcone JF, Fell MJ, Ryder JW, Yu H, Love PL, Katner J, Gordon KD, Wade MR, Man T, Nomikos GG, Phebus LA, Cauvin AJ, Johnson KW, Jones CK, Hoffmann BJ, Sandusky GE, Walter MW, Porter WJ, Yang L, Merchant KM, Shannon HE, Svensson KA.

Neuropharmacology. 2008 Oct;55(5):743-54. doi: 10.1016/j.neuropharm.2008.06.016. Epub 2008 Jun 17.

PMID:
18602930
29.

Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine.

Vlachou S, Stamatopoulou F, Nomikos GG, Panagis G.

Int J Neuropsychopharmacol. 2008 Nov;11(7):905-23. doi: 10.1017/S1461145708008717. Epub 2008 Apr 1.

PMID:
18377702
30.

Oral administration of the antiobesity drugs, sibutramine and rimonabant, increases acetylcholine efflux selectively in the medial prefrontal cortex of the rat.

Davis RJ, Nomikos GG.

Mol Psychiatry. 2008 Mar;13(3):240-1. doi: 10.1038/sj.mp.4002112. No abstract available.

PMID:
18285757
31.

The vesicular glutamate transporter VGLUT3 synergizes striatal acetylcholine tone.

Gras C, Amilhon B, Lepicard EM, Poirel O, Vinatier J, Herbin M, Dumas S, Tzavara ET, Wade MR, Nomikos GG, Hanoun N, Saurini F, Kemel ML, Gasnier B, Giros B, El Mestikawy S.

Nat Neurosci. 2008 Mar;11(3):292-300. doi: 10.1038/nn2052. Epub 2008 Feb 17.

PMID:
18278042
32.

Individual responses to novelty are associated with differences in behavioral and neurochemical profiles.

Antoniou K, Papathanasiou G, Papalexi E, Hyphantis T, Nomikos GG, Spyraki C, Papadopoulou-Daifoti Z.

Behav Brain Res. 2008 Mar 5;187(2):462-72. Epub 2007 Oct 22.

PMID:
18036673
33.

Behavioral and biochemical responses to d-amphetamine in MCH1 receptor knockout mice.

Smith DG, Qi H, Svenningsson P, Wade M, Davis RJ, Gehlert DR, Nomikos GG.

Synapse. 2008 Feb;62(2):128-36.

PMID:
18000809
34.
35.

Functional alterations of nicotinic neurotransmission in dopamine transporter knock-out mice.

Weiss S, Tzavara ET, Davis RJ, Nomikos GG, Michael McIntosh J, Giros B, Martres MP.

Neuropharmacology. 2007 Jun;52(7):1496-508. Epub 2007 Feb 24.

PMID:
17433376
36.

Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation.

Svenningsson P, Tzavara ET, Qi H, Carruthers R, Witkin JM, Nomikos GG, Greengard P.

J Neurosci. 2007 Apr 11;27(15):4201-9.

37.

In vivo neurochemical effects induced by changes in endocannabinoid neurotransmission.

Degroot A, Nomikos GG.

Curr Opin Pharmacol. 2007 Feb;7(1):62-8. Epub 2006 Dec 15. Review.

PMID:
17174603
38.

Cannabinoid CB1 receptor antagonism modulates plasma corticosterone in rodents.

Wade MR, Degroot A, Nomikos GG.

Eur J Pharmacol. 2006 Dec 3;551(1-3):162-7. Epub 2006 Sep 12.

PMID:
17030030
39.

Effects of endocannabinoid neurotransmission modulators on brain stimulation reward.

Vlachou S, Nomikos GG, Panagis G.

Psychopharmacology (Berl). 2006 Oct;188(3):293-305. Epub 2006 Sep 5.

PMID:
16953388
40.
41.

CB1 receptor antagonism increases hippocampal acetylcholine release: site and mechanism of action.

Degroot A, Köfalvi A, Wade MR, Davis RJ, Rodrigues RJ, Rebola N, Cunha RA, Nomikos GG.

Mol Pharmacol. 2006 Oct;70(4):1236-45. Epub 2006 Jul 19.

PMID:
16855179
42.

The procholinergic effects of the atypical antipsychotic olanzapine are independent of muscarinic autoreceptor inhibition.

Tzavara ET, Bymaster FP, Nomikos GG.

Mol Psychiatry. 2006 Jul;11(7):619-21. No abstract available.

PMID:
16801977
43.

Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.

Dickason-Chesterfield AK, Kidd SR, Moore SA, Schaus JM, Liu B, Nomikos GG, Felder CC.

Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):407-23. Epub 2006 May 31.

PMID:
16736384
44.

Effects of acute and subchronic d-amphetamine on ventral striatal concentrations of neurotensin and neuropeptide Y in rats treated with antipsychotic drugs.

Gruber SH, Nomikos GG, Mathé AA.

Eur Neuropsychopharmacol. 2006 Dec;16(8):592-600. Epub 2006 Mar 9.

PMID:
16524702
45.

Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody.

Bales KR, Tzavara ET, Wu S, Wade MR, Bymaster FP, Paul SM, Nomikos GG.

J Clin Invest. 2006 Mar;116(3):825-32. Epub 2006 Feb 23.

46.

Genetic deletion of muscarinic M4 receptors is anxiolytic in the shock-probe burying model.

Degroot A, Nomikos GG.

Eur J Pharmacol. 2006 Feb 15;531(1-3):183-6.

PMID:
16455072
47.

Alterations in 5-HT1B receptor function by p11 in depression-like states.

Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M, Vaugeois JM, Nomikos GG, Greengard P.

Science. 2006 Jan 6;311(5757):77-80.

48.

The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats.

Need AB, Davis RJ, Alexander-Chacko JT, Eastwood B, Chernet E, Phebus LA, Sindelar DK, Nomikos GG.

Psychopharmacology (Berl). 2006 Jan;184(1):26-35. Epub 2005 Nov 18.

PMID:
16328376
49.

Identification of a high-affinity binding site involved in the transport of endocannabinoids.

Moore SA, Nomikos GG, Dickason-Chesterfield AK, Schober DA, Schaus JM, Ying BP, Xu YC, Phebus L, Simmons RM, Li D, Iyengar S, Felder CC.

Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17852-7. Epub 2005 Nov 28.

50.

A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders.

Witkin JM, Tzavara ET, Davis RJ, Li X, Nomikos GG.

Trends Pharmacol Sci. 2005 Dec;26(12):609-17. Epub 2005 Nov 2.

PMID:
16260047

Supplemental Content

Loading ...
Support Center